Johnson & Johnson JNJ

$267.61 +9.83 (3.81%)

Valuation

Market cap
625,031,104,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.83
Forward PE
22.83
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
10,127,801
Avg volume
6,844,928
Day's range
$259.04 – $269.67
Shares out
2,409,898,000
Stochastic %K
66%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Outcomes Oct 22, 10:22 PM
$IBRX $JNJ $MRK $MRNA $PFE …when your foundation is faulty
1 replies
Outcomes Oct 22, 10:20 PM
$IBRX $JNJ $MRK $MRNA $PFE Seems mRNA ‘cancer vax’ off to same start as COVID & flu. Moderna brain trust trying to figure out how to spin. Beware Big Pharma. SAVE THE CHILDREN 🙏🏻
0 replies
Outcomes Oct 22, 10:16 PM
$IBRX $JNJ $MRK $MRNA $PFE When will it end?? Or, with spike replication…is the worst still ahead as has been warned? https://x.com/julie4butte5/status/2113143517795266789?s=46
1 replies
TopOptionAlert Oct 22, 8:48 PM
$JNJ NOV20 265C · update Called at $255.56 on Oct 19, now $267.61 (plus 4.7%). First objective at $264.39 is done, and the second objective at $281.07 is the level from here. P.S. Watch whether price holds over $264.39 into tomorrow, friend, because holding that first objective keeps the road toward $281.07 open.
0 replies
topstockalerts Oct 22, 8:44 PM
Johnson & Johnson reported strong early real-world results for its pulsed field ablation technology at the 2026 Asia Pacific Heart Rhythm Society Annual Meeting in Busan, South Korea. The VARIPURE study, involving more than 225 patients across 19 European centers using the VARIPULSE Pro platform, achieved 100% acute procedural success and a low primary adverse-event rate of 0.4%. Separately, 12-month data from the Omny-IRE study showed that 82.5% of patients remained free from atrial fibrillation recurrence under strict monitoring criteria. Both studies were published in the peer-reviewed journals Europace and Heart Rhythm, strengthening the clinical evidence behind J&J’s electrophysiology portfolio. Analyst sentiment has also been supportive. Wells Fargo raised its price target to $287 from $275 while maintaining an Overweight rating, and other analysts reiterated Buy recommendations, citing pharmaceutical growth. $JNJ
0 replies
USStockDesk Oct 22, 7:11 PM
$SOXL $SOXX Added more in $JNJ and $IBM
0 replies
BigFishEatLittleFish Oct 22, 6:48 PM
$MRNA who’s buying ❓ $MU $AMD $JNJ $NVDA
0 replies
BigFishEatLittleFish Oct 22, 6:42 PM
$JNJ ripping 🚀🚀❗️
0 replies